Head injury

The role of helmets in skiing and snowboarding

P McCrory

Helmets need to be developed using injury data and suitable standards

If a suitable helmet was available, then who would benefit? The highest risk groups would be ski racers, ski jumpers, freestyle aerialists, and children in all categories of skiing. The evidence that adult recreational skiers would benefit by helmets is not proven. Fortunately catastrophic ski injury, although tragic, is rare. The risk of injury is reducing at all ski resorts over time and this may have more to do with slope maintenance and grooming, improved ski equipment, improved skill development through ski school instruction, skier fitness, and education. There is probably still much to do in terms of slope control—for example, restricting or removing ski passes from skiers who violate the skier responsibility code by skiing too fast, out of control, or dangerously placing themselves as well as other slope users at risk.

At the present time no suitable helmet exists which is likely to protect all skiers and snowboarders. Although theoretically attractive in reducing head injury rates, the idea of skiers obtaining inferior and potentially dangerous helmets should not be encouraged. Better injury data analysis and suitable helmet standards are required to initiate the process of developing an appropriate protective helmet. Significant head injuries are rare in skiing and snowboarding and even if all participants wore helmets, it would not eliminate fatal injuries and may potentially increase the rate of other neurological injuries.


Author’s affiliations

P McCrory, Centre for Sports Medicine Research and Education and the Brain Institute, University of Melbourne, Melbourne, Australia

Correspondence to: Dr McCrory, PO Box 93, Shoreham, Victoria 3916, Australia; pmccrory@compuserve.com

REFERENCES

Tendon healing: can it be optimised?

N Maffulli, H D Moller, C H Evans

Growth factors may be useful in tendon healing, possibly introduced using gene therapy

Tendon disorders are a major problem in sports and occupational medicine. Tendons have the highest tensile strength of all connective tissue because of a high proportion of collagen in the fibres and their closely packed parallel arrangement in the direction of force. The individual collagen fibrils are arranged into fascicles which contain blood vessels and nerve fibres. Specialised fibroblasts, tenocytes, lie within these fascicles and exhibit high structural organisation. Histologically, they appear as star shaped cells in cross sections. In longitudinal sections, they are arranged in rows following the direction of the tendon fibres. This specialised arrangement is related to their function, as tenocytes synthesise both fibrillar and non-fibrillar components of the extracellular matrix, and are able to reabsorb collagen fibrils. The fascicles themselves are enclosed by epitelen. This is surrounded by the paratenon, and the potential space between them is filled by a thin, lubricating film of fluid which allows gliding of the tendon during motion.

BIOLOGY OF TENDON HEALING

Tendon healing is classically considered to occur through extrinsic and intrinsic healing. The intrinsic model produces obliteration of the tendon and its tendon sheath. Healing of the defect involves an exudative and a formative phase which, on the whole, are very similar to those associated with wound healing. Extrinsic healing occurs through the chemotaxis of the specialised fibroblasts into the defect from the ends of the tendon sheath. The process can be divided into three phases: inflammation, repair, and organisation or remodelling. In the inflammatory phase, occurring three to seven days after the injury, cells migrate from the extrinsic periosteum, subcutaneous tissue, and fascia, as well as from the epitelen and endotenon. Initially, the extrinsic response far outweighs the intrinsic one. This results in the rapid filling of the defect with granulation tissue, tissue debris, and haematoma. The migrating fibroblasts still play a phagocytic role, and are arranged in a radial fashion in relation to the direction of the fibres of the tendon. Biomechanical stability is given by fibrin. The migrated fibroblasts begin to synthesise collagen around day 5. Initially, these collagen fibres are randomly orientated. Tenocytes become the main cell type, and over the next five weeks collagen is continuously synthesised. During the 4th week, a noticeable increase in proliferation of fibroblasts of intrinsic origin, mainly from the endotenon, takes place. These cells take over the main role in the healing process and both synthesise and reabsorb collagen. The newly formed tissue starts to mature, and the collagen fibres are increasingly orientated along the direction of force through the tendon. This phase of repair continues for two months after the initial injury. Final stability is acquired during the remodelling induced by the normal physiological use of the tendon. This further orientates the fibres into the direction of force. In addition, cross linking between the collagen fibrils increases the tendon tensile strength. During the repair phase, the mechanically stronger type 1 collagen is produced in preference to type 3 collagen, thus slightly altering the initial ratio of these fibres to increase the strength of the repair.

Despite intensive remodelling over the following months, complete regeneration of the tendon is never achieved. The tissue replacing the defect remains hypocellular. The diameter of the collagen fibrils is altered, favouring thinner fibrils with reduction in the biomechanical strength of the tendon.

In tendinopathy and ruptured Achilles tendons, there is a reduction in the proportion of type 1 collagen, and a significant increase in the amount of type 3 collagen, responsible for the reduced tensile strength of the new tissue which is due to a reduced number of cross links compared with type 1 collagen. Recurring microinjuries lead to the development of hypertrophied biologically inferior tissue replacing the intact tendon.

CYTOKINETIC MODULATION OF TENDON HEALING

Growth factors and other cytokines play a key role in the embryonic differentiation of tissue and in the healing of tissues. Growth factors stimulate cell proliferation and chemotaxis, and aid angiogenesis, influencing cell differentiation. They regulate cellular synthetic and secretory activity of components of extracellular matrix. Finally, they influence the process of wound healing.

In the normal flexor tendon of the dog, the levels of basic fibroblast growth factor are higher than the levels of platelet derived growth factor (PDGF). In injured tendons, the converse is true. Under the influence of PDGF, chemotaxis and the rate of proliferation of fibroblasts and collagen synthesis are increased. Fibroblasts of the patellar tendon show increased proliferation in vitro after the administration of basic fibroblast growth factor. In addition, an angiogenic effect is evident. During the embryogenesis of tendon, bone morphogenetic proteins (BMP), especially BMP 12 and 13, cause increased expression of elastin and collagen type 1. Also, animal studies have shown that BMP 12 exerts a positive effect on the healing processes of the patellar tendon.

The growth factors of the transforming growth factor β superfamily induce an increase in mRNA expression of type 1 collagen and fibronectin in cell culture experiments.

High expression of collagen type 1 seems to be essential to achieve faster healing of tendons. Consequently, there should be a shift from the initial production of collagen type 3 to type 1 early in the healing process. The aforementioned growth factors could potentially be used to influence the processes of regeneration of tendons therapeutically. However, it is unlikely that a single growth factor will give a positive result. The interaction of many factors present in the right concentration at the right time will be necessary.

GENE THERAPY TO PROVIDE GROWTH FACTORS

Growth factors have a limited biological half life. Given the complexity of the healing process of tendons, a single application of growth factors is unlikely to be successful. As there is no bioavailability of oral proteins, repeated local injections would be necessary to maintain levels in the therapeutic range. This can be technically difficult in operatively treated tendons. The transfer of genes for the relevant growth factors seems an elegant alternative. After cellular uptake and expression of genes, a high level of the mediators can be locally produced and secreted.

To achieve this goal, vectors are used enabling the uptake and expression of genes into target cells. Vectors can be broadly grouped into viral and non-viral. Viral vectors are viruses deprived of their ability to replicate, into which the required genetic material can be inserted. They are effective, as the introduction of their genetic material into host cells forms part of their normal life cycle. Non-viral vectors have specific characteristics that enable penetration of the nucleus—for example, liposomal transport. The genes are released in the vicinity of the target cells without systemic dilution.
There are two main strategies for transfer using vectors. In in vivo transfer, the vectors are applied directly to the relevant tissue. In vitro transfer involves removal of cells from the body, the gene transfer in vitro, and subsequent culture of these cells before they are reintroduced into the target site. Direct transfer is less invasive and technically easier, and can be started during treatment of the acute phase of the injury. A disadvantage is the non-specific infection of cells during the injection process. In addition, owing to the amount of extracellular matrix present, a vector with high transgenic activity is necessary to be able to transfer the gene to enough cells.

Indirect transfer of genes is safer. The relevant cell type is isolated and genetically modified. Before reintroduction into the body, cells can be selected and tested for quality. This technique is more suitable for quality. Owing to the work involved in the body, cells can be selected and tested for quality. Owing to the process, there are several limitations. First, the cells are not able to survive in the body. Second, the vectors used may not be as effective as those used in vitro. Third, the amount of gene transfer may be limited.

In summary, tendon healing, even when successful, does not result in normal tendon. Mostly, the result is functionally satisfactory despite morphological differences and biomechanical weakness compared with a normal tendon. The therapeutic use of growth factors by gene transfer seems promising in the quest to produce a new tendon that is biologically, biomechanically, and physiologically "normal". Br J Sports Med 2002;36:315–316

Authors’ affiliations
N Maffulli, Department of Trauma and Orthopaedic Surgery, Keele University School of Medicine, Staffordshire, UK
H D Moller, Orthopaedische Klinik, Medizinische Hochschule im Anlass/Stift e.V., Hannover, Germany
C H Evans, Center for Molecular Orthopaedics, Harvard Medical School, Boston, MA, USA
Correspondence to: Professor Maffulli, Department of Trauma and Orthopaedic Surgery, Keele University School of Medicine, North Staffordshire Hospital, Thornaby Drive, Hartshill, Stoke on Trent, Staffordshire ST7 9QB, UK; osa14@keele.ac.uk

REFERENCES
Expression of concern about content of which Dr Paul McCrory is a single author

This paper is authored by Dr Paul McCrory. During 2021 and 2022 there was an investigation by BJSM and BMJ which found that some of his work was the product of publication misconduct. Such misconduct includes plagiarism, duplicate publication, misquotation and misrepresentation in publications in respect of which he was listed as the sole author. We are placing a notice to readers on all content in relation to which he is identified as the sole author to alert them to the conclusions of our investigation.

REFERENCE